PMID- 12087451
OWN - NLM
STAT- MEDLINE
DCOM- 20020802
LR  - 20220331
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 86
IP  - 11
DP  - 2002 Jun 5
TI  - Serum tryptophan decrease correlates with immune activation and impaired quality 
      of life in colorectal cancer.
PG  - 1691-6
AB  - Cancer-related indoleamine (2,3)-dioxygenase up-regulation by interferon-gamma 
      might influence quality of life by depleting serum tryptophan. We correlated 
      serum tryptophan levels with immune activation and quality of life in patients 
      with colorectal liver metastases. Venous blood was sampled from patients with 
      primary colorectal cancer and from patients with metachronous colorectal liver 
      metastases who completed quality of life and psychological questionnaires. Serum 
      tryptophan, kynurenine, neopterin, interleukin 2 soluble receptor alpha (IL-2 
      sRalpha), soluble tumour necrosis factor receptor I (sTNF RI), interleukin 6, and 
      C-reactive protein were measured. Liver metastasis volume was estimated by 
      computerised tomography, and survival from blood sampling was noted. Sixty-six 
      patients with colorectal cancer were studied (39 males; median age 66 years) of 
      whom 25 had colorectal liver metastases only (17 males; median age 62 years; 
      median liver metastasis volume 208 ml; median survival 234 days). Reduced serum 
      tryptophan was significantly associated with Rotterdam Symptom Checklist physical 
      symptom (r=-0.51, P=0.01) and Sickness Impact Profile (r=-0.42, P=0.04) scores, 
      and correlated with increased serum neopterin (r=-0.36, P=0.003), IL-2 sRalpha 
      (r=-0.51, P=0.01) and sTNF RI (r=-0.45, P=0.02) levels. Stepwise regression 
      analyses suggested that serum tryptophan was an independent predictor of 
      Rotterdam Symptom Checklist physical symptom (regression coefficient -20.78, 
      P=0.01) and Sickness Impact Profile (regression coefficient -109.09, P=0.04) 
      scores. The results supported a role for interferon-gamma-mediated serum 
      tryptophan decrease in cancer-induced quality of life deterioration.
CI  - Copyright 2002 Cancer Research UK
FAU - Huang, A
AU  - Huang A
AD  - Department of Surgery, Faculty of Medicine, Imperial College of Science, 
      Technology and Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, 
      London SW10 9NH, UK.
FAU - Fuchs, D
AU  - Fuchs D
FAU - Widner, B
AU  - Widner B
FAU - Glover, C
AU  - Glover C
FAU - Henderson, D C
AU  - Henderson DC
FAU - Allen-Mersh, T G
AU  - Allen-Mersh TG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 343-65-7 (Kynurenine)
RN  - 8DUH1N11BX (Tryptophan)
SB  - IM
MH  - Adenocarcinoma/blood/immunology/physiopathology/psychology
MH  - Aged
MH  - Colonic Neoplasms/blood/*immunology/physiopathology/psychology
MH  - Colorectal Neoplasms/blood/*immunology/physiopathology/psychology
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Kynurenine/blood
MH  - Liver Neoplasms/pathology/secondary
MH  - Middle Aged
MH  - *Quality of Life
MH  - Rectal Neoplasms/blood/*immunology/physiopathology/psychology
MH  - Regression Analysis
MH  - Survival Analysis
MH  - Tryptophan/*blood
MH  - Tumor Necrosis Factor-alpha/analysis
PMC - PMC2375406
EDAT- 2002/06/28 10:00
MHDA- 2002/08/03 10:01
CRDT- 2002/06/28 10:00
PHST- 2001/09/27 00:00 [received]
PHST- 2002/03/15 00:00 [revised]
PHST- 2002/04/08 00:00 [accepted]
PHST- 2002/06/28 10:00 [pubmed]
PHST- 2002/08/03 10:01 [medline]
PHST- 2002/06/28 10:00 [entrez]
AID - 6600336 [pii]
AID - 10.1038/sj.bjc.6600336 [doi]
PST - ppublish
SO  - Br J Cancer. 2002 Jun 5;86(11):1691-6. doi: 10.1038/sj.bjc.6600336.